Celgene Corporation (CELG) Holdings Trimmed by Logan Capital Management Inc.

Logan Capital Management Inc. decreased its holdings in Celgene Corporation (NASDAQ:CELG) by 2.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 98,009 shares of the biopharmaceutical company’s stock after selling 2,116 shares during the period. Logan Capital Management Inc.’s holdings in Celgene were worth $12,728,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in CELG. Capital Counsel LLC NY grew its position in shares of Celgene by 0.4% during the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 6 shares in the last quarter. Sowell Financial Services LLC grew its position in shares of Celgene by 0.5% during the 1st quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 13 shares in the last quarter. South Texas Money Management Ltd. grew its position in shares of Celgene by 0.6% during the 1st quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 15 shares in the last quarter. Flagship Harbor Advisors LLC grew its position in shares of Celgene by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 18 shares in the last quarter. Finally, Savant Capital LLC grew its position in shares of Celgene by 0.9% during the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 20 shares in the last quarter. Institutional investors and hedge funds own 80.17% of the company’s stock.

Celgene Corporation (NASDAQ:CELG) opened at $102.56 on Wednesday. Celgene Corporation has a 12 month low of $94.55 and a 12 month high of $147.17. The stock has a market capitalization of $80,786.59, a PE ratio of 16.03, a PEG ratio of 0.79 and a beta of 1.78. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period last year, the business posted $1.58 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. research analysts anticipate that Celgene Corporation will post 6.67 EPS for the current year.

A number of equities research analysts recently weighed in on CELG shares. William Blair reaffirmed an “outperform” rating on shares of Celgene in a research report on Friday, October 20th. Leerink Swann reaffirmed a “buy” rating and set a $156.00 price objective on shares of Celgene in a research report on Friday, October 20th. Piper Jaffray Companies reaffirmed a “neutral” rating and set a $133.00 price objective on shares of Celgene in a research report on Monday, October 23rd. Wells Fargo & Company downgraded Celgene from an “outperform” rating to a “market perform” rating in a research report on Thursday, October 26th. Finally, Vetr downgraded Celgene from a “buy” rating to a “hold” rating and set a $145.17 price objective on the stock. in a research report on Wednesday, September 6th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the stock. Celgene presently has an average rating of “Buy” and a consensus target price of $139.57.

In related news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) Holdings Trimmed by Logan Capital Management Inc.” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/12/06/celgene-corporation-celg-holdings-trimmed-by-logan-capital-management-inc.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply